Du är här

2016-02-02

Apricus Biosciences, Inc.: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference

SAN DIEGO, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that Richard Pascoe, Chief
Executive Officer, will present at the 18th Annual BIO CEO&Investor
Conference on Monday, February 8, 2016, at 9:30 a.m. Eastern Time. The
conference will be held at The Waldorf Astoria, New York, NY. Mr. Pascoe
will provide an update on Vitaros®, the Company's topical treatment for
erectile dysfunction, as well as Apricus' drug candidates fispemifene, for
the treatment of men with secondary hypogonadism and RayVa(TM), for the
treatment of patients with Raynaud's phenomenon.

A live audio webcast of the presentation can be accessed via the Investor
Relations section of the Company's website at www.apricusbio.com. Please log
in approximately 5-10 minutes before the event to ensure a timely connection.
A replay of the webcast will be available for 30 days following the
presentation.

About Apricus Biosciences, Inc

.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus recently completed
enrollment in its Phase 2b trial for fispemifene, a selective estrogen
receptor modulator for the treatment of symptomatic male secondary
hypogonadism, and plans to conduct additional studies in other urological
conditions. Apricus has completed a Phase 2a trial for RayVa(TM), its product
candidate for the treatment of the circulatory disorder Raynaud's phenomenon,
and plans to conduct additional clinical trials in patients with Raynaud's
phenomenon secondary to scleroderma. Apricus' lead commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Europe
and Canada and is being commercialized in several countries in Europe.
Apricus recently in-licensed the U.S. development and commercialization
rights for Vitaros from Allergan. Apricus' marketing partners for Vitaros
include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda
Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati
S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and
Mylan NV. Apricus' second-generation room temperature Vitaros is currently
under development.

For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Institutional / Retail Investors: Matthew Beck

mbeck@troutgroup.com
The Trout Group LLC
(646) 378-2933

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

HUG#1982912

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.